Paul M. Barr MD Associate Professor of Medicine at Wilmot Cancer Institute provides his opinion on ibrutinib in 1st line chronic lymphocytic leukemia (CLL).
Opinion on Ibrutinib on 1st Line CLL
Paul M. Barr MD Associate Professor of Medicine at Wilmot Cancer Institute provides his opinion on ibrutinib in 1st line chronic lymphocytic leukemia (CLL).